Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Nexlizet

Chemical Namebempedoic acid and ezetimibe
Dosage FormTablet (oral; bempedoic acid/ezetimibe: 180 mg/10 mg)
Drug ClassMultiple
SystemCardiovascular
CompanyEsperion
Approval Year2020

Indication

  • Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Document TitleYearSource
Nexlizet (bempedoic acid and ezetimibe) Prescribing Information.2021Esperion Therapeutics, Inc., Ann Arbor, MI
Document TitleYearSource
Network meta‐analysis of randomized trials evaluating the comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of low‐density lipoprotein cholesterol. 2022Journal of the American Heart Association
Bempedoic acid’s use as an adjunct in lowering low-density lipoprotein cholesterol in patients with coronary artery disease: a systematic review.2022Cureus
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia.2021NICE
Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value.2021ICER
Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: a systematic review and meta-analysis of randomized phase II/III trials.2021Clinical Drug Investigation
Assessment report: Nustendi.2020EMA
Efficacy and safety of bempedoic acid alone or combining with other lipid lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.2020BMC Pharmacology and Toxicology
Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials.2020European Journal of Preventive Cardiology
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis.2020PLOS Medicine
Document TitleYearSource
VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2020Department of Veterans Affairs Department of Defense
Drug updated on 5/31/2023

More on this drug: Clinical Trials